S
Seed Therapeutics
Biotech & Life Sciences · New York City, United States · Founded 2019
Pioneering the science of improving human health MoreLess
Seed Therapeutics is a pioneering biotech company focused on developing novel therapies that degrade disease-causing proteins, particularly those that have been difficult to target with traditional small molecule drugs. The company operates in the biopharmaceutical market, primarily serving patients with cancer and other serious diseases. Seed Therapeutics collaborates with leading research institutions and pharmaceutical companies, such as Lilly, to advance its drug candidates towards clinical and commercial success. The business model involves research and development of proprietary drug candidates, followed by licensing agreements and partnerships to bring these therapies to market. Revenue is generated through milestone payments, royalties, and licensing fees from these collaborations.
Keywords: protein degradation, novel therapies, cancer treatment, biopharmaceutical, drug development, research collaboration, licensing agreements, proprietary drugs, molecular glue, KRAS oncogene.
Company overview
Seed Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- New York City, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 85.6
Valuation & funding
Seed Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2025 | $6M | $120M | Undisclosed | ↗ |
| SECONDARY✓Other financing | Jan 2025 | $35M | — | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Aug 2024 | $24M | $96M | Eisai | ↗ |
| SPINOUT✓Other financing | Jan 2019 | $0 | — | New York University Grossman School of Medicine · University of Washington | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 27 |
| 2025 | 16 |
| 2024 | 16 |
| 2023 | 14 |
| 2022 | 10 |
Growth signals
Seed Therapeutics website traffic
Latest recorded traffic for Seed Therapeutics is 2.6K monthly website visits, up 100% over the last three months. Seed Therapeutics's team grew 56.3% over the past year.
Comparisons
Seed Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Seed Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Seed Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Seed Therapeutics has talent and traffic
team presence
In the news
Latest news about Seed Therapeutics
Recent press, funding announcements, and product moves mentioning Seed Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Seed Therapeutics
An AI-synthesized read of the highest-engagement posts about Seed Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Seed Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.